Insider Transactions in Q1 2023 at Hca Healthcare, Inc. (HCA)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 17
2023
|
Joseph A Sowell Iii SVP; Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,441
-32.12%
|
$639,542
$262.84 P/Share
|
|
Feb 17
2023
|
Joseph A Sowell Iii SVP; Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,600
+50.0%
|
-
|
|
Feb 17
2023
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,844
-6.46%
|
$483,128
$262.84 P/Share
|
|
Feb 17
2023
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
BUY
Grant, award, or other acquisition
|
Direct |
6,080
+17.55%
|
-
|
|
Feb 17
2023
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,356
-9.34%
|
$355,272
$262.84 P/Share
|
|
Feb 17
2023
|
Kathleen M Whalen SVP & Chief Ethics Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,560
+23.9%
|
-
|
|
Feb 17
2023
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Open market or private sale
|
Direct |
1,734
-14.83%
|
$456,042
$263.61 P/Share
|
|
Feb 17
2023
|
Christopher F. Wyatt SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
2,393
-6.22%
|
$626,966
$262.84 P/Share
|
|
Feb 17
2023
|
Christopher F. Wyatt SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
6,080
+13.65%
|
-
|
|
Feb 17
2023
|
Samuel N Hazen CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
36,770
-18.33%
|
$9,633,740
$262.84 P/Share
|
|
Feb 17
2023
|
Samuel N Hazen CEO |
BUY
Grant, award, or other acquisition
|
Direct |
94,880
+32.12%
|
-
|
|
Feb 17
2023
|
Mike A Marks EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,847
-17.69%
|
$483,914
$262.84 P/Share
|
|
Feb 17
2023
|
Mike A Marks EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
6,080
+36.8%
|
-
|
|
Feb 17
2023
|
Timothy M Mc Manus Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,438
-11.29%
|
$638,756
$262.84 P/Share
|
|
Feb 17
2023
|
Timothy M Mc Manus Group President |
BUY
Grant, award, or other acquisition
|
Direct |
7,600
+26.04%
|
-
|
|
Feb 17
2023
|
Sammie S Mosier SVP & Chief Nurse Executive |
SELL
Payment of exercise price or tax liability
|
Direct |
273
-3.39%
|
$71,526
$262.84 P/Share
|
|
Feb 17
2023
|
Sammie S Mosier SVP & Chief Nurse Executive |
BUY
Grant, award, or other acquisition
|
Direct |
1,120
+12.2%
|
-
|
|
Feb 17
2023
|
P. Martin Paslick SVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,589
-11.48%
|
$940,318
$262.84 P/Share
|
|
Feb 17
2023
|
P. Martin Paslick SVP and CIO |
BUY
Grant, award, or other acquisition
|
Direct |
9,120
+22.58%
|
-
|
|
Feb 17
2023
|
Deborah M Reiner SVP - Mktg. & Communications |
SELL
Payment of exercise price or tax liability
|
Direct |
1,246
-27.32%
|
$326,452
$262.84 P/Share
|
|
Feb 17
2023
|
Deborah M Reiner SVP - Mktg. & Communications |
BUY
Grant, award, or other acquisition
|
Direct |
4,560
+50.0%
|
-
|
|
Feb 17
2023
|
Bill B Rutherford CFO and EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
9,563
-9.03%
|
$2,505,506
$262.84 P/Share
|
|
Feb 17
2023
|
Bill B Rutherford CFO and EVP |
BUY
Grant, award, or other acquisition
|
Direct |
24,300
+18.66%
|
-
|
|
Feb 17
2023
|
Phillip G Billington SVP-Internal Audit Services |
SELL
Payment of exercise price or tax liability
|
Direct |
1,247
-2.76%
|
$326,714
$262.84 P/Share
|
|
Feb 17
2023
|
Phillip G Billington SVP-Internal Audit Services |
BUY
Grant, award, or other acquisition
|
Direct |
4,560
+9.16%
|
-
|
|
Feb 17
2023
|
Jeffrey E. Cohen SVP-Government Relations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,652
-21.83%
|
$432,824
$262.84 P/Share
|
|
Feb 17
2023
|
Jeffrey E. Cohen SVP-Government Relations |
BUY
Grant, award, or other acquisition
|
Direct |
4,560
+37.61%
|
-
|
|
Feb 17
2023
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,232
-12.83%
|
$1,108,784
$262.84 P/Share
|
|
Feb 17
2023
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,160
+26.94%
|
-
|
|
Feb 17
2023
|
Jon M Foster EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,768
-25.32%
|
$2,035,216
$262.84 P/Share
|
|
Feb 17
2023
|
Jon M Foster EVP and COO |
BUY
Grant, award, or other acquisition
|
Direct |
19,740
+39.15%
|
-
|
|
Feb 17
2023
|
Richard A Hammett Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,414
-18.68%
|
$894,468
$262.84 P/Share
|
|
Feb 17
2023
|
Richard A Hammett Group President |
BUY
Grant, award, or other acquisition
|
Direct |
9,680
+22.81%
|
-
|
|
Feb 17
2023
|
Erol R Akdamar Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,110
-6.33%
|
$814,820
$262.84 P/Share
|
|
Feb 17
2023
|
Erol R Akdamar Group President |
BUY
Grant, award, or other acquisition
|
Direct |
9,300
+15.93%
|
-
|
|
Feb 17
2023
|
Jennifer Berres SVP & Chief Human Res. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,441
-16.28%
|
$639,542
$262.84 P/Share
|
|
Feb 17
2023
|
Jennifer Berres SVP & Chief Human Res. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,600
+33.64%
|
-
|
|
Feb 16
2023
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,467
-9.89%
|
$648,821
$263.15 P/Share
|
|
Feb 16
2023
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
BUY
Exercise of conversion of derivative security
|
Direct |
4,575
+15.5%
|
$462,075
$101.16 P/Share
|
|
Feb 07
2023
|
Jennifer Berres SVP & Chief Human Res. Officer |
SELL
Open market or private sale
|
Direct |
4,000
-35.11%
|
$1,020,000
$255.23 P/Share
|
|
Feb 03
2023
|
Samuel N Hazen CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
32,208
-23.36%
|
$8,309,664
$258.08 P/Share
|
|
Feb 03
2023
|
Samuel N Hazen CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
59,000
+29.97%
|
$4,012,000
$68.96 P/Share
|
|
Feb 03
2023
|
Sammie S Mosier SVP & Chief Nurse Executive |
SELL
Payment of exercise price or tax liability
|
Direct |
41
-0.59%
|
$10,578
$258.08 P/Share
|
|
Feb 03
2023
|
Sammie S Mosier SVP & Chief Nurse Executive |
BUY
Exercise of conversion of derivative security
|
Direct |
138
+1.94%
|
-
|
|
Feb 03
2023
|
Deborah M Reiner SVP - Mktg. & Communications |
SELL
Open market or private sale
|
Direct |
7,941
-100.0%
|
$2,040,837
$257.61 P/Share
|
|
Feb 03
2023
|
Erol R Akdamar Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,932
-8.99%
|
$1,014,456
$258.08 P/Share
|
|
Feb 03
2023
|
Erol R Akdamar Group President |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+17.07%
|
$405,000
$45.3 P/Share
|
|
Feb 03
2023
|
Bill B Rutherford CFO and EVP |
SELL
Open market or private sale
|
Direct |
30,000
-26.87%
|
$7,740,000
$258.19 P/Share
|
|
Feb 02
2023
|
Erol R Akdamar Group President |
SELL
Open market or private sale
|
Direct |
3,000
-7.95%
|
$774,000
$258.63 P/Share
|
|
Feb 01
2023
|
Bill B Rutherford CFO and EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
34,895
-23.81%
|
$9,107,595
$261.46 P/Share
|